TRACON Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference
To access a live webcast of the presentation, please visit the “Events and Presentation” page within the “Investors” section of the
TRACON develops targeted therapies for cancer and ophthalmic diseases. The Company’s clinical-stage pipeline includes: TRC105, an endoglin antibody that is being developed for the treatment of multiple cancers; DE-122, the ophthalmic formulation of TRC105 that is being developed in wet AMD through a collaboration with
Chief Financial Officer
(858) 550‐0780 ext. 223
LifeSci Advisors LLC
Source: TRACON Pharmaceuticals, Inc.